Patents by Inventor James Elliot
James Elliot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160143874Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for exmaple. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.Type: ApplicationFiled: September 23, 2015Publication date: May 26, 2016Inventors: James Elliot Bradner, Ralph Mazitschek
-
Patent number: 9199923Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.Type: GrantFiled: March 6, 2014Date of Patent: December 1, 2015Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: James Elliot Bradner, Ralph Mazitschek
-
Patent number: 8988442Abstract: A method and an apparatus for notifying a display driver to update a display with a graphics frame including multiple graphics data rendered separately by multiple graphics processing units (GPUs) substantially concurrently are described. Graphics commands may be received to dispatch to each GPU for rendering corresponding graphics data. The display driver may be notified when each graphics data has been completely rendered respectively by the corresponding GPU.Type: GrantFiled: April 15, 2014Date of Patent: March 24, 2015Assignee: Apple Inc.Inventors: Michael James Elliot Swift, Kenneth Christian Dyke, Richard Warren Schreyer
-
Publication number: 20150038581Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.Type: ApplicationFiled: March 6, 2014Publication date: February 5, 2015Inventors: James Elliot Bradner, Ralph Mazitschek
-
Publication number: 20140213620Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.Type: ApplicationFiled: July 17, 2013Publication date: July 31, 2014Inventors: James Elliot Bradner, Ralph Mazitschek
-
Patent number: 8754237Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.Type: GrantFiled: July 16, 2012Date of Patent: June 17, 2014Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: James Elliot Bradner, Ralph Mazitschek, Weiping Tang, Stuart L. Schreiber
-
Patent number: 8720001Abstract: A tool for a surface treating appliance, such as a vacuum cleaner, includes a housing having a suction opening. An agitator, such as a brush bar, is rotatably located in the suction opening of the housing. The interior of such a tool can get blocked due to large objects being drawn in through the suction opening, or else by threads and fibers becoming tangled in the brush bar. The brush bar may be removed through the suction opening for replacement or repair. A portion of the housing may also be removable to clear the way for the user to access a narrow opening in the neck of the tool which may be prone to blockage.Type: GrantFiled: April 25, 2005Date of Patent: May 13, 2014Assignee: Dyson Technology LimitedInventors: Stephen Benjamin Courtney, Nicholas George Byatt, James Elliot Cameron
-
Patent number: 8716344Abstract: The present invention relates to compounds of the following formula wherein R3 is a fluorescent tag. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of the above formula in the presence of a test compound; and determining the activity of the HDAC protein.Type: GrantFiled: August 11, 2010Date of Patent: May 6, 2014Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Ralph Mazitschek, James Elliot Bradner
-
Publication number: 20130331455Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide synthetic methods for preparing the inventive compounds.Type: ApplicationFiled: April 12, 2013Publication date: December 12, 2013Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: Weiping Tang, James Elliot Bradner, Stuart L. Schreiber
-
Patent number: 8593467Abstract: A method of managing multiple contexts for a single mode display includes receiving a plurality of tasks from one or more applications and determining respective contexts for each task, each context having a range of memory addresses. The method also includes selecting one context for output to the single mode display and loading the selected context into a graphics processor for the display.Type: GrantFiled: October 10, 2012Date of Patent: November 26, 2013Assignee: Apple Inc.Inventors: Richard Warren Schreyer, Michael James Elliot Swift
-
Publication number: 20130261023Abstract: The present invention provides compositions and methods to facilitate the identification of compounds that are capable of interacting with a biological macromolecule of interest. In one aspect, a composition is provided that comprises an array of one or more types of chemical compounds attached to a solid support using isocyanate or isothiocyanate chemistry, wherein the density of the array of compounds is at least 1000 spots per cm2.Type: ApplicationFiled: October 10, 2012Publication date: October 3, 2013Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: David W. Barnes, Angela N. Koehler, James Elliot Bradner, Ralph Mazitschek, Stuart L. Schreiber
-
Patent number: 8440716Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide synthetic methods for preparing the inventive compounds.Type: GrantFiled: July 22, 2009Date of Patent: May 14, 2013Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Weiping Tang, James Elliot Bradner, Stuart L. Schreiber
-
Patent number: 8383855Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.Type: GrantFiled: February 14, 2007Date of Patent: February 26, 2013Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: James Elliot Bradner, Ralph Mazitschek
-
Publication number: 20130040998Abstract: Fluorinated deacetylase inhibitors of the general formulae (I), (II), and (III): and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase activity as described herein (e.g., cancer, neurodegenerative diseases, inflammatory diseases).Type: ApplicationFiled: January 5, 2011Publication date: February 14, 2013Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: James Elliot Bradner, Ralph Mazitschek
-
Publication number: 20130018103Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.Type: ApplicationFiled: July 16, 2012Publication date: January 17, 2013Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: James Elliot Bradner, Ralph Mazitschek, Weiping Tang, Stuart S. Schreiber
-
Patent number: 8304451Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel inhibitors of histone deacetylases, tubulin deacetylases, and/or aggresome inhibitors, and pharmaceutically acceptable salts and derivatives thereof. The inventive compounds fall into two classes—“isotubacin” class and “isoisotubacin” class—all of which include a 1,3-dioxane core. The present invention further provides methods for treating disorders regulated by histone deacetylase activity, tubulin deacetylase activity, and/or the aggresome (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, protein degradation disorders, protein deposition disorders, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.Type: GrantFiled: May 2, 2007Date of Patent: November 6, 2012Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Ralph Mazitschek, Nicholas Paul Kwiatkowski, James Elliot Bradner
-
Publication number: 20120208889Abstract: HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain embodiments, the compounds of the invention selectively target either a class or isoform of the HDAC family. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of general formula (IIIc) in the presence of a test compound; and determining the activity of the HDAC protein.Type: ApplicationFiled: August 11, 2010Publication date: August 16, 2012Applicants: Dana-Farber Cancer Institue, Inc., President and Fellows of Harvard CollegeInventors: Ralph Mazitschek, James Elliot Bradner
-
Patent number: 8222423Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.Type: GrantFiled: February 14, 2007Date of Patent: July 17, 2012Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, Howard Hughes Medical InstituteInventors: James Elliot Bradner, Ralph Mazitschek, Tang Weiping, Stuart S. Schreiber
-
Patent number: 8011269Abstract: An actuator has a rotatable input member coupled to a drive member such that rotation of the rotatable input member under an input load causes rotation of the drive member on a first axis. The drive member is coupled to a driven member such that rotation of the drive member causes rotation of the driven member on a second axis which is laterally offset from the first axis. A coupling between the drive member and the driven member is arranged to provide a rotational reduction from the drive member to the driven member. The driven member is arranged for connection to a wire of a Bowden cable having a sleeve seatable in relation to a housing for the actuator such that rotation of the driven member causes extension or retraction of the cable.Type: GrantFiled: April 7, 2006Date of Patent: September 6, 2011Assignee: Capro Ltd.Inventors: Andrew James Elliot, Wayne Andrew Harris
-
Publication number: 20110172303Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide synthetic methods for preparing the inventive compounds.Type: ApplicationFiled: July 22, 2009Publication date: July 14, 2011Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: Weiping Tang, James Elliot Bradner, Stuart L. Schreiber